NHS Offers New Leukaemia 'Cure' Gene Therapy

The NHS is now offering a revolutionary CAR T-cell therapy, a new form of 'living medicine' designed to combat acute lymphoblastic leukaemia. This advanced treatment involves reprogramming a patient's own immune T-cells in a laboratory to specifically target and destroy cancer cells. Professor Peter Johnson highlighted that this therapy "boosts a patient's own immune system and then guides T-cells towards the cancer to kill it," offering extended, healthier lives.

Clinical trials for the new therapy, known as obecabtagene autoleucel (obe-cel), demonstrated remarkable success, with over three-quarters of patients entering remission. Importantly, this cutting-edge treatment comes with fewer side effects compared to conventional therapies, a significant advantage for patients like 19-year-old Harry Brown, who experienced remission with minimal adverse effects. This offers renewed hope for individuals diagnosed with this aggressive form of leukaemia.

The treatment, approved by NICE, will be available to eligible patients aged 26 and over with relapsed or refractory B-cell acute lymphoblastic leukaemia. Its unique manufacturing in Stevenage, UK, marks a significant achievement in British medical innovation. The NHS, as the first health service in Europe to offer CAR T-cell therapy in 2018, continues to lead in providing advanced cancer treatments.